New lupus drug alnuctamab enters early human testing
NCT ID NCT07219563
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug, alnuctamab, in 21 people with moderate to severe lupus that hasn't improved with standard treatments. The drug is given as an injection under the skin, and participants will stay in the hospital for 9 days after the first dose. The main goals are to check safety and find the right dose, while also looking at whether it helps control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
alnuctamab (a drug given as an injection under the skin)
What this could lead to
If it works, this could point toward a new treatment option for people with lupus that hasn't responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 21 people, so it's mainly checking safety. It may not work, and side effects like cytokine release syndrome are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••